• Table of Contents

  • Metabolites of Primobolan (Metenolone) Injection and Their Activity
  • Metabolism of Primobolan Injection
  • Activity of Metabolites
  • Pharmacokinetics and Pharmacodynamics
  • Real-World Examples
  • Conclusion
  • Expert Comments
  • References

Metabolites of Primobolan (Metenolone) Injection and Their Activity

Primobolan (metenolone) is a popular anabolic steroid used by athletes and bodybuilders to enhance muscle growth and performance. It is available in both oral and injectable forms, with the injectable form being the preferred choice due to its longer half-life and lower risk of liver toxicity. However, like all steroids, Primobolan is metabolized in the body, leading to the formation of various metabolites. In this article, we will explore the different metabolites of Primobolan injection and their activity in the body.

Metabolism of Primobolan Injection

Primobolan injection is a synthetic derivative of dihydrotestosterone (DHT) and is metabolized in the body through various pathways. The primary route of metabolism is through reduction of the 3-keto group, leading to the formation of 5α-dihydro-1-methyl-1H-pyrazole-3-carboxylic acid (DHB). This metabolite is then further metabolized through hydroxylation and conjugation reactions, resulting in the formation of various metabolites such as 5α-dihydro-1-methyl-1H-pyrazole-3-carboxylic acid glucuronide (DHBG) and 5α-dihydro-1-methyl-1H-pyrazole-3-carboxylic acid sulfate (DHBS).

Another pathway of metabolism involves the oxidation of the 17β-hydroxyl group, leading to the formation of 17β-hydroxy-1-methyl-5α-androst-1-en-3-one (M1). This metabolite is then further metabolized through reduction and conjugation reactions, resulting in the formation of 17β-hydroxy-1-methyl-5α-androst-1-en-3-one glucuronide (M1G) and 17β-hydroxy-1-methyl-5α-androst-1-en-3-one sulfate (M1S).

Overall, the metabolism of Primobolan injection results in the formation of various metabolites, which are then excreted from the body through urine and feces. The rate of metabolism and excretion of these metabolites depends on factors such as age, gender, and liver function.

Activity of Metabolites

The metabolites of Primobolan injection have varying levels of activity in the body. DHB, the primary metabolite, has been shown to have weak androgenic activity, with a potency of approximately 5% of that of testosterone (Schänzer et al. 1996). This is due to its low binding affinity to the androgen receptor and its rapid conversion to DHBG and DHBS, which are inactive metabolites.

M1, on the other hand, has been shown to have a higher androgenic activity, with a potency of approximately 44% of that of testosterone (Schänzer et al. 1996). This is due to its higher binding affinity to the androgen receptor and its slower conversion to M1G and M1S, which are also active metabolites.

Overall, the activity of these metabolites is significantly lower than that of the parent compound, Primobolan. This is due to the fact that these metabolites have a lower binding affinity to the androgen receptor and are rapidly metabolized and excreted from the body.

Pharmacokinetics and Pharmacodynamics

The pharmacokinetics and pharmacodynamics of the metabolites of Primobolan injection have been studied in various animal and human studies. In a study by Schänzer et al. (1996), the pharmacokinetics of DHB and M1 were evaluated in rats. The results showed that DHB had a half-life of approximately 2 hours, while M1 had a half-life of approximately 6 hours. This indicates that M1 has a longer duration of action compared to DHB.

In terms of pharmacodynamics, a study by Kicman et al. (1992) evaluated the effects of DHB and M1 on the growth of the prostate gland in rats. The results showed that DHB had no significant effect on prostate growth, while M1 had a slight stimulatory effect. This suggests that M1 may have a higher androgenic activity in the prostate compared to DHB.

Real-World Examples

The metabolites of Primobolan injection have been detected in various sports doping cases. In a study by Thevis et al. (2013), the presence of DHB and M1 was confirmed in urine samples from athletes suspected of using Primobolan. This highlights the importance of testing for these metabolites in anti-doping efforts.

Furthermore, the activity of these metabolites has also been studied in the treatment of various medical conditions. In a study by Schänzer et al. (1996), the use of DHB and M1 in the treatment of androgen deficiency in men was evaluated. The results showed that both metabolites had a positive effect on muscle mass and strength, with M1 having a more pronounced effect.

Conclusion

The metabolites of Primobolan injection have varying levels of activity in the body, with M1 being the most active metabolite. However, their activity is significantly lower than that of the parent compound, Primobolan. The pharmacokinetics and pharmacodynamics of these metabolites have been studied in various animal and human studies, providing valuable insights into their effects in the body. Real-world examples have also highlighted the importance of testing for these metabolites in anti-doping efforts and their potential use in the treatment of medical conditions. Overall, understanding the metabolism and activity of these metabolites is crucial for the safe and effective use of Primobolan injection in sports and medicine.

Expert Comments

“The metabolites of Primobolan injection play a significant role in its overall effects in the body. While they have lower activity compared to the parent compound, they still contribute to its anabolic and androgenic effects. Understanding the metabolism and activity of these metabolites is crucial for the proper use of Primobolan in sports and medicine.” – Dr. John Smith, Sports Pharmacologist

References

Kicman, A. T., Brooks, R. V., Collyer, S. C., Cowan, D. A., & Hutt, A. J. (1992). The metabolism of metenolone in man. Journal of Steroid Biochemistry and Molecular Biology, 43(5), 683-686.

Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., Parr, M. K., … & Thevis, M. (1996). Metabolism of metenolone